AU2021264554B2 - Compounds and methods for prevention and treatment of coronavirus infections - Google Patents

Compounds and methods for prevention and treatment of coronavirus infections

Info

Publication number
AU2021264554B2
AU2021264554B2 AU2021264554A AU2021264554A AU2021264554B2 AU 2021264554 B2 AU2021264554 B2 AU 2021264554B2 AU 2021264554 A AU2021264554 A AU 2021264554A AU 2021264554 A AU2021264554 A AU 2021264554A AU 2021264554 B2 AU2021264554 B2 AU 2021264554B2
Authority
AU
Australia
Prior art keywords
3clpro
sars
cov
acid
activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2021264554A
Other languages
English (en)
Other versions
AU2021264554A1 (en
Inventor
Hao Chiang
Wei-Chung CHIOU
Cheng Huang
Hui-Ju Liang
Pei-Hsin Lin
Jir-Mehng Lo
Yeh B. WU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arjil Biotech Holding Co Ltd
Original Assignee
Arjil Biotech Holding Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arjil Biotech Holding Co Ltd filed Critical Arjil Biotech Holding Co Ltd
Publication of AU2021264554A1 publication Critical patent/AU2021264554A1/en
Application granted granted Critical
Publication of AU2021264554B2 publication Critical patent/AU2021264554B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2021264554A 2020-05-01 2021-04-29 Compounds and methods for prevention and treatment of coronavirus infections Active AU2021264554B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063018690P 2020-05-01 2020-05-01
US63/018,690 2020-05-01
PCT/US2021/029840 WO2021222534A1 (en) 2020-05-01 2021-04-29 Compounds and methods for prevention and treatment of coronavirus infections

Publications (2)

Publication Number Publication Date
AU2021264554A1 AU2021264554A1 (en) 2023-01-05
AU2021264554B2 true AU2021264554B2 (en) 2026-05-21

Family

ID=78292168

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021264554A Active AU2021264554B2 (en) 2020-05-01 2021-04-29 Compounds and methods for prevention and treatment of coronavirus infections

Country Status (7)

Country Link
US (1) US12433901B2 (cg-RX-API-DMAC7.html)
EP (1) EP4142713A1 (cg-RX-API-DMAC7.html)
JP (1) JP7805010B2 (cg-RX-API-DMAC7.html)
CN (1) CN116568295B (cg-RX-API-DMAC7.html)
AU (1) AU2021264554B2 (cg-RX-API-DMAC7.html)
TW (1) TW202206080A (cg-RX-API-DMAC7.html)
WO (1) WO2021222534A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021311814A1 (en) * 2020-07-23 2023-03-02 Arjil Biotech Holding Company Limited Method and composition for inhibiting virus infection
WO2023065223A1 (zh) * 2021-10-21 2023-04-27 北京大学深圳研究生院 鱼针草酸在制备抑制新型冠状病毒与变异株的感染与复制的医药组合物中的用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100210869A1 (en) * 2009-02-13 2010-08-19 Kaohsiung Medical University Ethanol extract of antrodia camphorata for inducing apoptosis and preparation method thereof
US20140105928A1 (en) * 2004-01-06 2014-04-17 Paul Edward Stamets Antiviral and antibacterial activity from medicinal mushrooms
WO2020176436A1 (en) * 2019-02-25 2020-09-03 Arjil Biotech Holding Company Limited Method and composition for inhibiting virus infection

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2481489A1 (en) * 2002-11-29 2004-06-17 Morinaga Milk Industry Co., Ltd. Cysteine protease inhibitor
US7919665B2 (en) 2009-02-17 2011-04-05 Conocophillips Company Mercury removal from hydrocarbons
TW201231474A (en) * 2011-01-26 2012-08-01 Univ Kaohsiung Medical Triterpenoid composition of Antrodia cinnamomea, preparation and analysis method thereof
FI126047B (en) * 2012-08-28 2016-06-15 John Eriksson Pharmaceutical compositions of anisomelic acid and their use
TWI453026B (zh) * 2013-05-14 2014-09-21 Jenisa Biotechnology Corp Ltd 魚針草萃取物及其純化物抗流感病毒之用途
US9645651B2 (en) 2013-09-24 2017-05-09 Microsoft Technology Licensing, Llc Presentation of a control interface on a touch-enabled device based on a motion or absence thereof
US11779620B2 (en) * 2020-04-03 2023-10-10 Turtle Bear Holdings, Llc Combined fungal composition for modulating inflammatory response
CN113521060B (zh) * 2020-04-17 2022-12-06 北京大学深圳研究生院 鱼针草内酯抗新型冠状病毒的用途
WO2021218974A1 (en) * 2020-04-28 2021-11-04 Alps Biotech Co., Ltd. Uses of antrodia cinnamomea extract in manufacturing products for reducing expression and treating associated diseases of angiotensin converting enzyme 2

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140105928A1 (en) * 2004-01-06 2014-04-17 Paul Edward Stamets Antiviral and antibacterial activity from medicinal mushrooms
US20100210869A1 (en) * 2009-02-13 2010-08-19 Kaohsiung Medical University Ethanol extract of antrodia camphorata for inducing apoptosis and preparation method thereof
WO2020176436A1 (en) * 2019-02-25 2020-09-03 Arjil Biotech Holding Company Limited Method and composition for inhibiting virus infection

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WU CANRONG, et al: "Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods", ACTA PHARMACEUTICA SINICA B, vol. 10, no. 5, (2020), pages 766 - 788, DOI: 10.1016/j.apsb.2020.02.008 *

Also Published As

Publication number Publication date
TW202206080A (zh) 2022-02-16
US20210338690A1 (en) 2021-11-04
CN116568295A (zh) 2023-08-08
AU2021264554A1 (en) 2023-01-05
US12433901B2 (en) 2025-10-07
CN116568295B (zh) 2026-02-13
WO2021222534A1 (en) 2021-11-04
EP4142713A1 (en) 2023-03-08
JP2023524274A (ja) 2023-06-09
JP7805010B2 (ja) 2026-01-23

Similar Documents

Publication Publication Date Title
Wang et al. SARS-CoV-2: structure, biology, and structure-based therapeutics development
Haque et al. A comprehensive review about SARS-CoV-2
Xu et al. Broad spectrum antiviral agent niclosamide and its therapeutic potential
Kuo et al. Kinetic characterization and inhibitor screening for the proteases leading to identification of drugs against SARS-CoV-2
CN113289018B (zh) 金诺芬等老药及其组合物在抗单正链rna病毒中的应用
WO2021205296A1 (en) Method of treating covid-19
KR20220146558A (ko) 항-코로나바이러스에서의 디설피람의 용도
Ghosh et al. Progress in anti-SARS coronavirus chemistry, biology and chemotherapy
CN113262224A (zh) 奈非那韦在制备防治新冠肺炎药物中的应用
Kumar et al. A review of novel coronavirus disease (COVID-19): based on genomic structure, phylogeny, current shreds of evidence, candidate vaccines, and drug repurposing
US12433901B2 (en) Compounds and methods for prevention and treatment of coronavirus infections
KR20230011972A (ko) 코로나바이러스로 인한 질병을 치료 및/또는 예방하는 화합물 및 이의 용도
Kooshkaki et al. Coronavirus disease 2019: a brief review of the clinical manifestations and pathogenesis to the novel management approaches and treatments
JP7856325B2 (ja) ウイルス感染を予防および処置するための化合物および方法
Singh et al. COVID-19: pathophysiology, transmission, and drug development for therapeutic treatment and vaccination strategies
CN113893345A (zh) 247种化合物及其组合物在抗新型冠状病毒感染中的应用
CN113440527B (zh) 萘酚喹或含萘酚喹的组合制剂在抗冠状病毒中的应用
US11986478B2 (en) Targeting papain-like protease for broad-spectrum coronaviruses inhibition
US20230310369A1 (en) Method and composition for inhibiting virus infection
US20250214981A1 (en) Compound and application thereof in preparation of medicine for treating enterovirus-related diseases
RU2829731C1 (ru) Применение дисульфирама при резистентности коронавируса
Bajpai et al. The Biogenesis, Transmission, Structural and Therapeutics on SARS-CoV-2 (COVID-19) Pandemic: Challenges and Global Perspective. Research & Reviews: A Journal of Immunology. 2021; 11 (1): 8–23p
Barile et al. Therapeutic targeting of coronavirus spike glycoprotein priming
CN100478030C (zh) 抗传染性非典型性肺炎药物作用靶标及其预防和治疗药物
CN113893347A (zh) 1869种化合物及其组合物在抗新型冠状病毒感染中的应用